Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions focus on the findings of the study, such as reports that only 39.5% of patients mounted a positive antibody response after vaccination, with terms like 'low responses' and 'markedly impaired' illustrating the severity of the issue. Moreover, numerous users expressed concern regarding the timing of vaccinations relative to CLL treatments, indicating a strategic consideration for healthcare practices.
Many discussions reflect a consensus on the challenges faced by CLL patients regarding vaccine response, indicating a degree of support for the publication's findings.
There is considerable curiosity around the implications of the study, with users actively discussing its relevance to CLL patients.
While most comments share personal experiences, a handful dive into the specifics of the research, suggesting moderate depth of engagement.
Users perceive substantial implications for treatment plans and vaccination strategies for CLL patients, emphasizing the importance of this research.
多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia https://t.co/sp2edrbHTs
Patients with chronic lymphatic leukemia (CLL) respond poorly to mRNA #COVID19 vaccination, especially if they have been treated with BTK or BCL-2 inhibitors. https://t.co/nlkyUdD3Oy https://t.co/9RLe10tHCg
NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma" #lymsm @COVID19nCCC #ccc19 @mtmdphd @rubinstein_md @dgermain21 https://t.co/Sa611jJeWX https://t.co/8zaY8XGcsc
Useful study. Reduced antibody response to Pzifer vaccine in CLL patients, esp those on ibrutinib and venetoclax. Patients need disease-specific advice and counselling. Expect more similar studies to follow. https://t.co/1uA3Bsnizx
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al. @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #COVIDVaccine #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC HT @CyclingDoctor
Paper in the journal Blood shows that patients with chronic lymphatic leukaemia (CLL) respond less well to the Pfizer #COVID19 vaccine than healthy controls. https://t.co/146rCEMiQ1 1/2 https://t.co/70Za3aRQwn
This video delves into the principles of quantum mechanics, highlighting its fundamental concepts and real-world applications. Understand the behavior of particles at the quantum level and their implications in…
➡️ ctd.: https://t.co/2sb13bFw91 https://t.co/KFnF5np9AE https://t.co/Awyifl6shj https://t.co/96Rr66vSfd American Cancer Society: https://t.co/mexm1Xo0i6 Pharmacovigilance studies do not flag any safety concerns either. https://t.co/w37HS18Rds https://t.co/RCFYHVmcQo
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/65ELbiD7pX
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/Coat9MM05Q
RT @Asterisme_: @ConstansPierre @FLAHAULT Bien sûr que cela a été étudié et les bénéfices dépassent largement les risques ! Chez des pat…
RT @Asterisme_: @ConstansPierre @FLAHAULT Bien sûr que cela a été étudié et les bénéfices dépassent largement les risques ! Chez des pat…
@ConstansPierre @FLAHAULT Bien sûr que cela a été étudié et les bénéfices dépassent largement les risques ! Chez des patients immunodéprimés : https://t.co/vaSdRJGIqN Chez des patients atteints de leucémie lymphoïde chronique : https://t.co/aJW4nbaQf6 1/3
@stayone10 @barriere_dr @FranckRamus @raoult_didier Chez des patients immunodéprimés : https://t.co/a5n8WydjBT Chez des patients atteints de leucémie lymphoïde chronique : https://t.co/aJW4nbaQf6 Chez des patients atteints de maladies rhumatismales inflammatoires auto-immunes : https://t.co/vEpkrYKY6R
@EnemyInAState It is known that people with CLL do not mount a good antibody response to the mRNA vaccines. I am not sure if the reason for this is known. My husband had CLL, and I follow this very closely. https://t.co/AMs0lnrc5m
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with #ChronicLymphocyticLeukemia: A #Serologic and Cellular Study ➡️ https://t.co/FOYDiQutPM ✍️ Stefano Molica et al.
@JScholar אגב, ההמטולוג שלי השתתף במחקר על יעילות החיסון של פייזר בחולי CLL, שהראה שחולים שטופלו בריטוקסימב פחות מ-12 חודשים לפני החיסון לא פיתחו רמת נוגדנים מספקת. https://t.co/Yl2VkFV4kX
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study by Stefano Molica https://t.co/nzx8cgLoay
New article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study https://t.co/zXIREzdO8k #CLL #leusm #hematology
@eosull @NobleGuardianIE @JanRynne Thanks Eileen. Studies are ongoing. Yes CLL patients have lower antibody response and many on treatment have zero antibodies. We are hoping the booster will help patients but its early days. https://t.co/3RMdzY4FVi
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
RT @CyclingDoctor: NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2…
NHL patients receiving anti-CD20 therapy are unlikely to achieve a humoral response to vaccine "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma" #lymsm @COVID19nCCC #ccc19 @mtmdphd @rubinstein_md @dgermain21 https://t.co/Sa611jJeWX https://t.co/8zaY8XGcsc
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma | Blood Advances | American Society of Hematology https://t.co/dJCz1OR213
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. https://t.co/V2hGVvVMtR
RT @Lymphoma_Papers: Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma #lymphoma #lymsm https://t…
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma #lymphoma #lymsm https://t.co/BH8FCe4mKV
@DanielleHammo20 Does this mean our within-one-year-of-Rituximab patients didn't make the list? :( Not the world's best evidence (22 patients), but their vaccine responses seem to not be great. https://t.co/YZVn7JOz2n
@Paula14152 @Chrissip81 @DrHadlich @florian_krammer @CiesekSandra Ein paar Daten sind zu dem Thema auch schon publiziert, z. B. hier: https://t.co/Cf36pX1Ito
@WorldOfBenjamin @cynnabun73 @Chicago_Scanner For what it’s worth… https://t.co/uem7NreeEp
https://t.co/WeMTzZkKMv
RT @ShrimpTail_Tx: 拝見したTwの論文
拝見したTwの論文
RT @mtmdphd: Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https:/…
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/ibHV03HfQI
RT @mtmdphd: Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https:/…
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/GdqDYKoEPC
@authorpendragon @JoyCannabis https://t.co/tBA2w03sgr
@AJGregory_tenor Clearly reduced antibody responses. But generally fine in patient in remission. Relatively small study, but good to have data. https://t.co/8UuYwu4Tsq https://t.co/s5fMdKCipp
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/uVERNAHXxK
@PaolaGhione_MD @BloodJournal @RoswellPark @PallawiTorkaMD @SSundaramMD @goelship @Francis77605164 https://t.co/tMLmdqnb0V https://t.co/OVPSQoMSNd
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al. @BloodJournal https://t.co/C3gvhTQtFN #COVID19Vaccine #COVID19nCancer #CCC19 #geriheme #CLLsm #leusm https://t.co/XnwIwxoTJi
@akikigate Chronic Lymphocytic Leukemia and vaccine efficacy: https://t.co/Ssn3PV3SJT
@LS94012515 @akikigate Chronic Lymphocytic Leukemia and vaccine efficacy: https://t.co/Ssn3PV3SJT
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology https://t.co/zufaVOq59E
@TheWatcher_007 @urenacard @nuriapiera https://t.co/hexp9PmKaa https://t.co/3neG30bS7V https://t.co/t6yFque3lP https://t.co/F2aeOqnM3P
Antibody-mediated response to the #BNT162b2 mRNA COVID-19 vaccine in patients with #CLL is markedly impaired and affected by disease activity and treatment. This trial was registered at https://t.co/WQh2uV6gsS as #NCT04746092. https://t.co/e5FlqIGnIV
RT @DrMDavids: Important new study for CLL patients to be aware of: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chroni…
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al.…
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al.…
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al.…
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al.…
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al. @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #COVIDVaccine #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC HT @CyclingDoctor
@KDAO2011 This publication suggests that patients on Rituximab (or at least those with CLL) may not get a significant response to the COVID vaccine for at least a year following their last Rituximab treatment. https://t.co/YZVn7JwXDN
RT @mtmdphd: Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https:/…
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/cYSoTxiKzQ
@chaminadejp Oui
RT @freshblooddr: Useful study. Reduced antibody response to Pzifer vaccine in CLL patients, esp those on ibrutinib and venetoclax. Patient…
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology https://t.co/SROiXEaTaO
"In a total of 167 patients with CLL, the antibody response rate was 39.5%." @BloodJournal Last Oct when we asked @MDAndersonNews to help us with a #GS441524 trial, possibly via leukemia dept, they told us this would provide "no benefit" smh #COVID19 https://t.co/FZubJK7nmj https://t.co/QNqMYrULss
Less than robust responses especially if on active therapy. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | ASH https://t.co/MGpnDhncxw
RT @CyclingDoctor: Antibody response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired Treatment with Bruton’s…
Useful study. Reduced antibody response to Pzifer vaccine in CLL patients, esp those on ibrutinib and venetoclax. Patients need disease-specific advice and counselling. Expect more similar studies to follow. https://t.co/1uA3Bsnizx
Efficacy of COVID-19 vaccine in patients with CLL is very low-39.5% https://t.co/u3DByCIgil https://t.co/d7JyNDjVA0
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0% https://t.co/TUhc0xpArE
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al.…
Efficacy of @BioNTech_Group @pfizer BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] @herishanu et al @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC Ab response markedly impaired & affected by disease activity & Tx https://t.co/TTPl16tZkq
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] @herishanu et al. @BloodJournal https://t.co/FDK9EzcZ46 #NCT04746092 #COVID19nCancer #COVIDVaccine #CLLsm #leusm #CCC19 #COVID19 @COVID19nCCC HT @CyclingDoctor https://t.co/BJUXjwGBdq
RT @ProfMakris: Patients with chronic lymphatic leukemia (CLL) respond poorly to mRNA #COVID19 vaccination, especially if they have been tr…
Patients with chronic lymphatic leukemia (CLL) respond poorly to mRNA #COVID19 vaccination, especially if they have been treated with BTK or BCL-2 inhibitors. https://t.co/nlkyUdD3Oy https://t.co/9RLe10tHCg
RT @CyclingDoctor: Antibody response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired Treatment with Bruton’s…
RT @CyclingDoctor: Antibody response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired Treatment with Bruton’s…
@Crosshead16 @Mom_and_Paul Ja, auf jeden Fall impfen. Einen negativen Effekt durch die Impfung wird es nicht geben, auch wenn bei Erwachsenen eine schwächere Immunantwort beschrieben ist: https://t.co/Cf36pX1Ito
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia | Blood | American Society of Hematology.Ab-mediated response to BNT162b2 mRNA COVID-19 vaccine in CLL impaired and affected by disease activity and treatment. https://t.co/wrvG1lrtvR
Antibody response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL is markedly impaired Treatment with Bruton’s tyrosine kinase inhibitors or venetoclax ± anti-CD20 antibody leads to low antibody response. #CLL #leusm @COVID19nCCC https://t.co/AVRn2Fyfyz
10/ COVID-19 vaccine responses in CLL Rx with/without anti-CD20 “Ab response to BNT162b2 mRNA vaccine in CLL patients is impaired and affected by disease activity and treatment.” “No patient on anti-CD20 Rx <12 mo prior to vaccination responded.” https://t.co/fyUQH4SU4b
#ThisWeekToday 1. CLL Patients May Have Lower Response to COVID-19 Vaccines (source: https://t.co/OYJOpR0QbQ ) 2. NCCN recommends Brukinsa for chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL). (source: https://t.co/1Ip9C9NUNj ) https://t.co/2o42hGjsQu
RT @HematologyArm: @sanz_guille @HematoLaFe @sehh_es Yes Guillermo, we already knew that from a previous published experience con CLL patie…
@sanz_guille @HematoLaFe @sehh_es Yes Guillermo, we already knew that from a previous published experience con CLL patients whose therapy backbone was rituximab. If respiratory symptoms in our patients ask fod RT-PCR for SARS-cov-2, https://t.co/hNyaSVII66
@Working17705685 @lottefrosch Das ist hier für CLL-Patienten beschrieben. Rituximab hat ja eine lange Halbwertszeit. https://t.co/JV4DnbbvEJ
RT @hrkz1985: 167名のCLL患者でファイザーワクチンの効果を検討：ファイザーワクチン接種によるスパイク蛋白に対するIgG：39.5%で上昇、治療によって完解している場合：79.2%、治療を行っていない場合：55.2%、治療中：16%。 https://t.co…
RT @hrkz1985: 167名のCLL患者でファイザーワクチンの効果を検討：ファイザーワクチン接種によるスパイク蛋白に対するIgG：39.5%で上昇、治療によって完解している場合：79.2%、治療を行っていない場合：55.2%、治療中：16%。 https://t.co…
RT @hrkz1985: 167名のCLL患者でファイザーワクチンの効果を検討：ファイザーワクチン接種によるスパイク蛋白に対するIgG：39.5%で上昇、治療によって完解している場合：79.2%、治療を行っていない場合：55.2%、治療中：16%。 https://t.co…
167名のCLL患者でファイザーワクチンの効果を検討：ファイザーワクチン接種によるスパイク蛋白に対するIgG：39.5%で上昇、治療によって完解している場合：79.2%、治療を行っていない場合：55.2%、治療中：16%。 https://t.co/RYbBOJ8jF7
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
@celtic_traveler @DaveKronig Science. Data. https://t.co/H7vNNvMQkK
RT @mtmdphd: @Dorry_Segev Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @heri…
@Dorry_Segev Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al. @BloodJournal https://t.co/C3gvhTQtFN #COVID19Vaccine #COVID19nCancer #CCC19 #geriheme #CLLsm #leusm HT @ADesaiMD
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
Pfizer/Moderna vaccines may not work well for people with CLL like me. I had the AstraZeneca first dose before I knew about this research. https://t.co/ctrxuCaOdw
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
RT @influenzer3: 多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccin…
多くの免疫不全者を防御するためには、mRNAワクチンだけでは不十分である可能性が高そうです。 抗体カクテル製剤による受動免疫ができる体制が望まれるかと。 Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia https://t.co/sp2edrbHTs
@SkinMD13 @EricTopol 1) I said "some"; and my comment is based on more than that one story (even though not statistically significant). 2) This is about more than people on immunosuppressive drugs. https://t.co/mRxAxMY6es
#Antibodies matter. But in CLL, antibody response to #vaccine is poor https://t.co/HILHc0p8ba via @BloodJournal #Tcell data encouraging! https://t.co/j0AHTW7ek6 via @MonicaGandhi9 But do #vaccines produce T-cell response in #CLL? Dr. Gandhi? @ASH_hematology? @EHA_Hematology? https://t.co/AZ5zae9v2o
why people in Pakistan should get vaccine at this Point in Time? https://t.co/hCa3O3alcu via @YouTube
Knowing what we know about the efficacy of #CovidVaccine in #CLL pts based on the recent @BloodJournal pub, how have you adjusted you treatment approach for CLL pts? https://t.co/Q5nqjcaSYR
¿qué sabemos de la respuesta inmune a la vacuna mRNA en los pacientes con #LLC? @sehh_es Predictores de ac-neutralizantes: jóvenes, mujeres, libre de tratamiento, IgG ≥550 mg/dL e IgM ≥40mg/dL.https://t.co/O5uXhwIJiK
@DrMiguelPerales Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al. @BloodJournal https://t.co/C3gvhTQtFN #COVID19Vaccine #COVID19nCancer #CCC19 #geriheme #CLLsm #leusm
#CLL & #COVID19 #vaccine: Antibody response = poor https://t.co/HILHc0p8ba via @BloodJournal Still, while #antibodies are easily measured, more important may be #Tcells (& #Bcells) Thoughts on #lymphocyte response in CLL? @profshanecrotty @MonicaGandhi9 @VirusesImmunity @LLSusa https://t.co/PH9l7E5tEY
@KPlorable @just_mindy @kc_digiacomo https://t.co/Y6YIB9HHDH
@FineUrlaub Das weiss ja meines Wissens nach keiner so recht. Es gibt ja Daten bei CLL-Patienten, wo die Antikörperbildung deutlich reduziert ist: https://t.co/JV4DnbbvEJ
RT @CllIreland: @RTE_PrimeTime @LeoVaradkar @MiriamOCal Solution: Those that live with blood cancer patients should be considered for vacci…
@RTE_PrimeTime @LeoVaradkar @MiriamOCal Solution: Those that live with blood cancer patients should be considered for vaccination as these patients have a reduced response to the vaccine. Some on treatments have no detectible antibodies. @DonnellyStephen @FergalBowers @CMOIreland https://t.co/oCWqpGPwKl
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of Hematology https://t.co/u23xi6A1ps
Efficacy of the BNT162b2 mRNA #COVID19 vaccine in patients with chronic lymphocytic leukemia: https://t.co/3jtyuqx0m9
@michael_duerr @schrezenmeier @Julian_RinconA Same problem in CLL https://t.co/l60C9c0Nhj
@maribelpereiras https://t.co/DANUjzE8BA
RT @the_paper_link: Trend up+10: Herishanu Y, ..., Ghia P (Blood) __Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chroni…
Trend up+10: Herishanu Y, ..., Ghia P (Blood) __Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia__ https://t.co/mByu8CPQet
#Sinopharm #vaccine #Studies suggestive of 93-95 % immunity ( hospital free ) illness if infected with #Covid_19 https://t.co/fCrfs0sgDI
RT @NatRevClinOncol: Study reveals that antibody responses to BNT162b2 mRNA COVID19 vaccine in pts with CLL is markedly impaired and affect…
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al.…
RT @NatRevClinOncol: Study reveals that antibody responses to BNT162b2 mRNA COVID19 vaccine in pts with CLL is markedly impaired and affect…
RT @atscommunity: Efficacy of the BNT162b2 mRNA #COVID19 vaccine in patients with chronic lymphocytic leukemia: https://t.co/3jtyuqx0m9
Efficacy of the BNT162b2 mRNA #COVID19 vaccine in patients with chronic lymphocytic leukemia: https://t.co/3jtyuqx0m9
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al.…
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al. @BloodJournal https://t.co/C3gvhU84xl #COVID19Vaccine #COVID19nCancer #CCC19 #geriheme #CLLsm #leusm HT @ADesaiMD
RT @vjimenezyuste: Antibody response to mRNA COVID19 vaccine in CLL patients with is markedly impaired and affected by disease activity and…
RT @NatRevClinOncol: Study reveals that antibody responses to BNT162b2 mRNA COVID19 vaccine in pts with CLL is markedly impaired and affect…
Study reveals that antibody responses to BNT162b2 mRNA COVID19 vaccine in pts with CLL is markedly impaired and affected by disease activity and treatment: https://t.co/nRycfN6g3o. Another analysis suggest similar in elderly pts with MM: https://t.co/qvt5DYsIvO #COVID19andCancer
RT @vjimenezyuste: Antibody response to mRNA COVID19 vaccine in CLL patients with is markedly impaired and affected by disease activity and…
RT @vjimenezyuste: Antibody response to mRNA COVID19 vaccine in CLL patients with is markedly impaired and affected by disease activity and…
Antibody response to mRNA COVID19 vaccine in CLL patients with is markedly impaired and affected by disease activity and treatment. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia https://t.co/UQJ1WciaK0
RT @ProfMakris: Paper in the journal Blood shows that patients with chronic lymphatic leukaemia (CLL) respond less well to the Pfizer #COVI…
RT @ProfMakris: Paper in the journal Blood shows that patients with chronic lymphatic leukaemia (CLL) respond less well to the Pfizer #COVI…
RT @ProfMakris: Paper in the journal Blood shows that patients with chronic lymphatic leukaemia (CLL) respond less well to the Pfizer #COVI…
RT @ProfMakris: Paper in the journal Blood shows that patients with chronic lymphatic leukaemia (CLL) respond less well to the Pfizer #COVI…
Paper in the journal Blood shows that patients with chronic lymphatic leukaemia (CLL) respond less well to the Pfizer #COVID19 vaccine than healthy controls. https://t.co/146rCEMiQ1 1/2 https://t.co/70Za3aRQwn
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of Hematology. https://t.co/8xqXFI1Y3W
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al. @BloodJournal https://t.co/C3gvhTQtFN #COVID19Vaccine #COVID19nCancer #CCC19 #geriheme #CLLsm #leusm cc @IMFjimMYELOMA
RT @Fer_martinmoro: Efficacy of the BNT162b2 mRNA #COVID-19 Vaccine in pts with #CLL | @BloodJournal
RT @miguel78910: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. Baja respuesta de anticuerp…
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. Baja respuesta de anticuerpos a la vacuna COVID19 de ARNm de BNT162b2 en pacientes con CLL. Menos del 40% de estos pacientes con CLL tuvieron respuesta adecuada. https://t.co/z6pBQ1ajJM https://t.co/OVkAjO7BSk
RT @DrMDavids: Important new study for CLL patients to be aware of: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chroni…
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
RT @PharmDeetinib: ~50:50 serologic antibody response, but NO responses if exposed to CD-20 MAB in last year, low responses if on PO tx. Go…
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
RT @Kalikanzari: A new pair of studies suggest that mRNA-based Covid-19 vaccines may not work as well in people with chronic lymphocytic le…
RT @DrMDavids: Important new study for CLL patients to be aware of: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chroni…
Antibody response to BNT162b2 mRNA vaccine in CLL patients is markedly impaired and affected by disease activity and treatment. In a total of 167 patients with CLL who received two doses, response rate was only 39.5%. https://t.co/sfKvoicp6s
RT @CllIreland: Antibody response to BNT162b2 mRNA COVID19 vaccine in CLL patients is markedly impaired and affected by disease activity a…
RT @PharmDeetinib: ~50:50 serologic antibody response, but NO responses if exposed to CD-20 MAB in last year, low responses if on PO tx. Go…
RT @Othman_Al_Sawaf: Nice study by @herishanu et al @BloodJournal on Covid-vax in CLL:https://t.co/OvLR5O8BmJ - response rate 40% in 167 pt…
RT @PharmDeetinib: ~50:50 serologic antibody response, but NO responses if exposed to CD-20 MAB in last year, low responses if on PO tx. Go…
~50:50 serologic antibody response, but NO responses if exposed to CD-20 MAB in last year, low responses if on PO tx. Good news though if in remission and off treatment. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with CLL | Blood |https://t.co/7Aqz0iU60C
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al.…
RT @Othman_Al_Sawaf: Nice study by @herishanu et al @BloodJournal on Covid-vax in CLL:https://t.co/OvLR5O8BmJ - response rate 40% in 167 pt…
Efficacy of the BNT162b2 #mRNA #COVID19Vaccine in Patients with CLL. This suggests timing Pfizer vax around leukemia treatment is important for producing an AB response rate? https://t.co/PnvUo1k4PD
RT @mtmdphd: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al.…
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia [Apr 16, 2021] @herishanu et al. @BloodJournal https://t.co/C3gvhU84xl #COVID19Vaccine #COVID19nCancer #CCC19 #geriheme #CLLsm #leusm HT @ADesaiMD https://t.co/ALy1a0t5Mg
#COVID-19 Vaccine
RT @Transplant_Doc: Antibody response to BNT162b2 vaccine in CLL patients is markedly impaired and affected by disease activity and treatme…
MRNA vaccines may not offer as robust an antibody response in people with blood cancers Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of Hematology https://t.co/w19FlClX66
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
RT @DrMDavids: Important new study for CLL patients to be aware of: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chroni…
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
RT @VivekSubbiah: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society o…
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of Hematology https://t.co/ULn5rxtH2c
RT @DrMDavids: Important new study for CLL patients to be aware of: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chroni…
RT @DrMDavids: Important new study for CLL patients to be aware of: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chroni…
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
RT @tobyeyre82: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia | Blood | American Society of…
New article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia https://t.co/XmlV7bj2kR #CLL #leusm #hematology